S&P 500   3,843.16 (+0.36%)
DOW   31,191.47 (-0.67%)
QQQ   315.20 (+0.76%)
AAPL   123.42 (+2.01%)
MSFT   231.99 (+1.31%)
FB   262.26 (+2.97%)
GOOGL   2,022.15 (+0.31%)
AMZN   3,074.06 (+0.55%)
TSLA   681.48 (-0.11%)
NVDA   544.14 (+2.22%)
BABA   241.31 (+0.47%)
CGC   32.87 (-1.02%)
GE   12.68 (-0.63%)
MU   91.02 (+3.29%)
NIO   46.51 (-0.64%)
AMD   84.56 (+2.60%)
T   28.42 (-0.73%)
F   11.77 (+0.09%)
ACB   10.87 (+0.46%)
DIS   188.75 (-1.17%)
BA   214.06 (-1.10%)
NFLX   545.02 (-0.31%)
BAC   35.03 (-2.50%)
S&P 500   3,843.16 (+0.36%)
DOW   31,191.47 (-0.67%)
QQQ   315.20 (+0.76%)
AAPL   123.42 (+2.01%)
MSFT   231.99 (+1.31%)
FB   262.26 (+2.97%)
GOOGL   2,022.15 (+0.31%)
AMZN   3,074.06 (+0.55%)
TSLA   681.48 (-0.11%)
NVDA   544.14 (+2.22%)
BABA   241.31 (+0.47%)
CGC   32.87 (-1.02%)
GE   12.68 (-0.63%)
MU   91.02 (+3.29%)
NIO   46.51 (-0.64%)
AMD   84.56 (+2.60%)
T   28.42 (-0.73%)
F   11.77 (+0.09%)
ACB   10.87 (+0.46%)
DIS   188.75 (-1.17%)
BA   214.06 (-1.10%)
NFLX   545.02 (-0.31%)
BAC   35.03 (-2.50%)
S&P 500   3,843.16 (+0.36%)
DOW   31,191.47 (-0.67%)
QQQ   315.20 (+0.76%)
AAPL   123.42 (+2.01%)
MSFT   231.99 (+1.31%)
FB   262.26 (+2.97%)
GOOGL   2,022.15 (+0.31%)
AMZN   3,074.06 (+0.55%)
TSLA   681.48 (-0.11%)
NVDA   544.14 (+2.22%)
BABA   241.31 (+0.47%)
CGC   32.87 (-1.02%)
GE   12.68 (-0.63%)
MU   91.02 (+3.29%)
NIO   46.51 (-0.64%)
AMD   84.56 (+2.60%)
T   28.42 (-0.73%)
F   11.77 (+0.09%)
ACB   10.87 (+0.46%)
DIS   188.75 (-1.17%)
BA   214.06 (-1.10%)
NFLX   545.02 (-0.31%)
BAC   35.03 (-2.50%)
S&P 500   3,843.16 (+0.36%)
DOW   31,191.47 (-0.67%)
QQQ   315.20 (+0.76%)
AAPL   123.42 (+2.01%)
MSFT   231.99 (+1.31%)
FB   262.26 (+2.97%)
GOOGL   2,022.15 (+0.31%)
AMZN   3,074.06 (+0.55%)
TSLA   681.48 (-0.11%)
NVDA   544.14 (+2.22%)
BABA   241.31 (+0.47%)
CGC   32.87 (-1.02%)
GE   12.68 (-0.63%)
MU   91.02 (+3.29%)
NIO   46.51 (-0.64%)
AMD   84.56 (+2.60%)
T   28.42 (-0.73%)
F   11.77 (+0.09%)
ACB   10.87 (+0.46%)
DIS   188.75 (-1.17%)
BA   214.06 (-1.10%)
NFLX   545.02 (-0.31%)
BAC   35.03 (-2.50%)
Log in
OTCMKTS:ALPMY

Astellas Pharma News Headlines

$16.52
-0.31 (-1.84 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.45
Now: $16.52
$16.79
50-Day Range
$15.27
MA: $16.47
$17.41
52-Week Range
$12.48
Now: $16.52
$18.43
Volume45,402 shs
Average Volume83,346 shs
Market Capitalization$30.76 billion
P/E Ratio23.94
Dividend Yield1.72%
Beta0.63

Headlines

Astellas Pharma (OTCMKTS ALPMY) News Headlines Today

Source:
SourceHeadline
Astellas Pharma (OTCMKTS:ALPMY) Shares Pass Above Fifty Day Moving Average of $16.47Astellas Pharma (OTCMKTS:ALPMY) Shares Pass Above Fifty Day Moving Average of $16.47
americanbankingnews.com - February 26 at 4:18 AM
Astellas Pharmas Fezolinetant Topped Placebo For Reducing Severity Of Menopausal Hot Flash In Phase 3 StudiesAstellas Pharma's Fezolinetant Topped Placebo For Reducing Severity Of Menopausal Hot Flash In Phase 3 Studies
finance.yahoo.com - February 19 at 5:56 PM
Astellas Announces Positive Topline Results from Two Phase 3 Pivotal Global Trials of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Postmenopausal WomenAstellas Announces Positive Topline Results from Two Phase 3 Pivotal Global Trials of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Postmenopausal Women
finance.yahoo.com - February 19 at 12:55 PM
Seagen/Astellas Pharma Seek Approval For PADCEVs Expanded Use In Urothelial Cancer SettingsSeagen/Astellas Pharma Seek Approval For PADCEV's Expanded Use In Urothelial Cancer Settings
finance.yahoo.com - February 18 at 12:52 PM
Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Above Fifty Day Moving Average of $16.23Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Above Fifty Day Moving Average of $16.23
americanbankingnews.com - February 18 at 3:56 AM
Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Decrease in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Decrease in Short Interest
americanbankingnews.com - February 11 at 12:54 AM
Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Above 50-Day Moving Average of $15.87Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Above 50-Day Moving Average of $15.87
americanbankingnews.com - February 10 at 5:24 AM
Astellas XOSPATA® (gilteritinib) Receives Conditional Approval by Chinas National Medical Products Administration for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 MutationAstellas' XOSPATA® (gilteritinib) Receives Conditional Approval by China's National Medical Products Administration for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
finance.yahoo.com - February 4 at 12:53 AM
Jefferies Financial Group Comments on Astellas Pharma Inc.s FY2021 Earnings (OTCMKTS:ALPMY)Jefferies Financial Group Comments on Astellas Pharma Inc.'s FY2021 Earnings (OTCMKTS:ALPMY)
americanbankingnews.com - February 1 at 3:30 AM
Astellas Pharma Inc. 2021 Q3 - Results - Earnings Call PresentationAstellas Pharma Inc. 2021 Q3 - Results - Earnings Call Presentation
seekingalpha.com - January 29 at 3:30 PM
Astellas Achieves 100% Score on Corporate Equality Index for Seventh Consecutive YearAstellas Achieves 100% Score on Corporate Equality Index for Seventh Consecutive Year
finance.yahoo.com - January 28 at 5:36 PM
FDA Accepts for Priority Review the New Drug Application for mirabegron for Oral Suspension and Supplemental New Drug Application for Myrbetriq® (mirabegron) Tablets in Pediatric PatientsFDA Accepts for Priority Review the New Drug Application for mirabegron for Oral Suspension and Supplemental New Drug Application for Myrbetriq® (mirabegron) Tablets in Pediatric Patients
finance.yahoo.com - January 6 at 8:08 AM
Astellas Phase 3 Trial On Gilteritinib-Azacitidine Fails To Meet Primary Goal In FLT3mut+ AMLAstellas' Phase 3 Trial On Gilteritinib-Azacitidine Fails To Meet Primary Goal In FLT3mut+ AML
nasdaq.com - December 21 at 6:41 AM
Astellas Reports XOSPATA® (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction ChemotherapyAstellas Reports XOSPATA® (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
finance.yahoo.com - December 21 at 6:41 AM
KaliVir, Astellas Pharma Enter Licensing Agreement For VET2-L2 Oncolytic VirusKaliVir, Astellas Pharma Enter Licensing Agreement For VET2-L2 Oncolytic Virus
nasdaq.com - December 7 at 3:17 AM
Astellas Pharma: Roxadustat Approved In Japan For Adults With Anemia Of CKD Not On DialysisAstellas Pharma: Roxadustat Approved In Japan For Adults With Anemia Of CKD Not On Dialysis
nasdaq.com - November 27 at 3:57 AM
Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on DialysisAstellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
finance.yahoo.com - November 27 at 3:57 AM
Astellas to Present New Data on Gilteritinib in FLT3 Mutation-Positive Acute Myeloid Leukemia at the 2020 American Society of Hematology Annual MeetingAstellas to Present New Data on Gilteritinib in FLT3 Mutation-Positive Acute Myeloid Leukemia at the 2020 American Society of Hematology Annual Meeting
finance.yahoo.com - November 16 at 9:16 AM
Astellas Pharma Inc. 2020 Q2 - Results - Earnings Call PresentationAstellas Pharma Inc. 2020 Q2 - Results - Earnings Call Presentation
seekingalpha.com - November 1 at 4:46 AM
Astellas Pharma: FDA Grants Fast Track Designation For ASP5354 - Quick FactsAstellas Pharma: FDA Grants Fast Track Designation For ASP5354 - Quick Facts
nasdaq.com - October 28 at 9:14 AM
Astellas Receives U.S. FDA Fast Track Designation for ASP5354, an Investigational Near-Infrared Fluorescence Imaging AgentAstellas Receives U.S. FDA Fast Track Designation for ASP5354, an Investigational Near-Infrared Fluorescence Imaging Agent
finance.yahoo.com - October 28 at 9:14 AM
U.S. FDA Grants Fast Track Designation for ASP0367/MA-0211, a Selective PPARδ Modulator being Developed for the Treatment of Primary Mitochondrial MyopathiesU.S. FDA Grants Fast Track Designation for ASP0367/MA-0211, a Selective PPARδ Modulator being Developed for the Treatment of Primary Mitochondrial Myopathies
finance.yahoo.com - October 20 at 12:59 PM
New Roxadustat Data in Anemia of Chronic Kidney Disease to be Released at ASN Kidney Week 2020 ReimaginedNew Roxadustat Data in Anemia of Chronic Kidney Disease to be Released at ASN Kidney Week 2020 Reimagined
prnewswire.com - October 19 at 3:15 AM
Prostate Cancer Market Growing Trends and Demands Analysis forecast 2020 to 2026Prostate Cancer Market Growing Trends and Demands Analysis forecast 2020 to 2026
marketwatch.com - September 28 at 7:07 PM
Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial CancerAstellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - September 18 at 7:42 AM
Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial CancerSeattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - September 18 at 7:42 AM
arket To Witness the Highest Growth Globally in Coming Years 2020-2025arket To Witness the Highest Growth Globally in Coming Years 2020-2025
marketwatch.com - September 16 at 7:45 PM
Astellas Pharma Inc. -- Moody's announces completion of a periodic review of ratings of Astellas Pharma Inc.Astellas Pharma Inc. -- Moody's announces completion of a periodic review of ratings of Astellas Pharma Inc.
finance.yahoo.com - August 26 at 2:29 PM
Astellas Pharma Inc. 2020 Q1 - Results - Earnings Call PresentationAstellas Pharma Inc. 2020 Q1 - Results - Earnings Call Presentation
seekingalpha.com - August 6 at 7:46 AM
Astellas is Awarded Grant from the U.S. National Institutes of Health (NIH) to Fund Early Clinical Studies of ASP8062 to Investigate Potential Novel Therapeutic Approach to Address the Opioid CrisisAstellas is Awarded Grant from the U.S. National Institutes of Health (NIH) to Fund Early Clinical Studies of ASP8062 to Investigate Potential Novel Therapeutic Approach to Address the Opioid Crisis
finance.yahoo.com - July 22 at 1:28 PM
Japanese shares regain lost ground as growth stocks back in focusJapanese shares regain lost ground as growth stocks back in focus
finance.yahoo.com - June 18 at 10:32 PM
Japanese shares end almost flat just below 3-month high as rally loses steamJapanese shares end almost flat just below 3-month high as rally loses steam
finance.yahoo.com - June 18 at 10:32 PM
Overactive Bladder Treatment Market Competitive Research And Precise Outlook 2020 To 2025Overactive Bladder Treatment Market Competitive Research And Precise Outlook 2020 To 2025
www.marketwatch.com - June 18 at 1:28 AM
Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney DiseaseRoxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease
finance.yahoo.com - June 8 at 7:13 AM
Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate CancerFinal PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer
finance.yahoo.com - May 29 at 12:39 PM
XTANDI® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant MetastasisXTANDI® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
finance.yahoo.com - May 29 at 7:39 AM
FDA Approves VESIcare LS™ (solifenacin succinate) Oral Suspension for Pediatric PatientsFDA Approves VESIcare LS™ (solifenacin succinate) Oral Suspension for Pediatric Patients
finance.yahoo.com - May 27 at 6:08 PM
Atopic Dermatitis Therapeutics Market Competitive Research And Precise Outlook 2020 To 2026Atopic Dermatitis Therapeutics Market Competitive Research And Precise Outlook 2020 To 2026
www.marketwatch.com - May 25 at 1:18 PM
ASTELLAS PHARMA UNSP/ADR (ALPMY) - Insider TransactionsASTELLAS PHARMA UNSP/ADR (ALPMY) - Insider Transactions
www.fool.com - May 21 at 8:57 PM
European Medicines Agency Accepts Astellas Marketing Authorization Application for RoxadustatEuropean Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat
finance.yahoo.com - May 20 at 11:40 PM
Astellas Pharma Inc. ADRAstellas Pharma Inc. ADR
www.wsj.com - April 25 at 10:17 PM
Astellas Pharma Inc. -- Moodys downgrades Astellass issuer rating to A2; outlook negativeAstellas Pharma Inc. -- Moody's downgrades Astellas's issuer rating to A2; outlook negative
finance.yahoo.com - March 5 at 9:02 AM
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder CancerAstellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
finance.yahoo.com - February 19 at 8:48 AM
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder CancerSeattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer
finance.yahoo.com - February 10 at 7:58 PM
Astellas Completes Acquisition of Audentes TherapeuticsAstellas Completes Acquisition of Audentes Therapeutics
finance.yahoo.com - January 15 at 1:22 PM
Seattle Genetics' stock rises on approval of bladder cancer drugSeattle Genetics' stock rises on approval of bladder cancer drug
finance.yahoo.com - December 19 at 1:12 PM
Astellas Pharma Inc. -- Moodys reviews Astellas Pharmas A1 ratings for downgradeAstellas Pharma Inc. -- Moody's reviews Astellas Pharma's A1 ratings for downgrade
finance.yahoo.com - December 6 at 9:59 AM
Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative ScienceAstellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science
finance.yahoo.com - December 5 at 12:36 PM
Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual MeetingAstellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting
finance.yahoo.com - December 2 at 11:54 PM
This Gene Therapy Player Just Grabbed A $3 Billion Takeover BidThis Gene Therapy Player Just Grabbed A $3 Billion Takeover Bid
finance.yahoo.com - December 2 at 6:53 PM
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.